Journal
CIRCULATION RESEARCH
Volume 117, Issue 3, Pages 229-233Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1161/CIRCRESAHA.117.306306
Keywords
cell- and tissue-based therapy; clinical trial; chronic heart failure; heart disease; mesenchymal stem cells
Funding
- National Institutes of Health [R01HL110737, R01HL084275, R01HL094849, R01HL107110, UM1HL113460]
- Starr Foundation
- Soffer Family Foundation
Ask authors/readers for more resources
Cell-based treatment represents a new generation in the evolution of biological therapeutics. A prototypic cell-based therapy, the mesenchymal stem cell, has successfully entered phase III pivotal trials for heart failure, signifying adequate enabling safety and efficacy data from phase I and II trials. Successful phase III trials can lead to approval of a new biological therapy for regenerative medicine.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available